Sanofi — Director's Dealing 2015

Sep 25, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2015-09-23

Reporting Person: Sanofi (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-09-23	Common Stock	P	2600	$523.4327	Acquired	22872383	Indirect
2015-09-23	Common Stock	P	3211	$524.4477	Acquired	22875594	Indirect
2015-09-23	Common Stock	P	1200	$525.8842	Acquired	22876794	Indirect
2015-09-23	Common Stock	P	3472	$526.9029	Acquired	22880266	Indirect
2015-09-23	Common Stock	P	2573	$527.8528	Acquired	22882839	Indirect
2015-09-23	Common Stock	P	4694	$529.0410	Acquired	22887533	Indirect
2015-09-23	Common Stock	P	8689	$530.0952	Acquired	22896222	Indirect
2015-09-23	Common Stock	P	6043	$530.6769	Acquired	22902265	Indirect
2015-09-23	Common Stock	P	2544	$531.9284	Acquired	22904809	Indirect
2015-09-23	Common Stock	P	5945	$533.2330	Acquired	22910754	Indirect
2015-09-23	Common Stock	P	12828	$534.4185	Acquired	22923582	Indirect
2015-09-23	Common Stock	P	19042	$535.2162	Acquired	22942624	Indirect
2015-09-23	Common Stock	P	23423	$536.2586	Acquired	22966047	Indirect
2015-09-23	Common Stock	P	20730	$537.2133	Acquired	22986777	Indirect
2015-09-23	Common Stock	P	15274	$538.3122	Acquired	23002051	Indirect
2015-09-23	Common Stock	P	11212	$539.1918	Acquired	23013263	Indirect
2015-09-23	Common Stock	P	3729	$539.9825	Acquired	23016992	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").

F3: Purchase prices range from $523.04 to $523.90 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,217,440 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $524.14 to $525.09 per share, inclusive.

F6: Purchase prices range from $525.21 to $526.17 per share, inclusive.

F7: Purchase prices range from $526.26 to $527.22 per share, inclusive.

F8: Purchase prices range from $527.42 to $528.33 per share, inclusive.

F9: Purchase prices range from $528.46 to $529.44 per share, inclusive.

F10: Purchase prices range from $529.49 to $530.46 per share, inclusive.

F11: Purchase prices range from $530.48 to $531.18 per share, inclusive.

F12: Purchase prices range from $531.48 to $532.46 per share, inclusive.

F13: Purchase prices range from $532.78 to $533.77 per share, inclusive.

F14: Purchase prices range from $533.79 to $534.75 per share, inclusive.

F15: Purchase prices range from $534.78 to $535.77 per share, inclusive.

F16: Purchase prices range from $535.78 to $536.75 per share, inclusive.

F17: Purchase prices range from $536.78 to $537.75 per share, inclusive.

F18: Purchase prices range from $537.79 to $538.78 per share, inclusive.

F19: Purchase prices range from $538.81 to $539.79 per share, inclusive.

F20: Purchase prices range from $539.81 to $540.00 per share, inclusive.